Biogen raised to Buy at Goldman Sachs as Alzheimer’s prospects return

Oct. 26, 2022 10:39 AM ETBiogen Inc. (BIIB)RHHBY, LLY, ESALY, ESALF, RHHBFBy: Dulan Lokuwithana, SA News Editor1 Comment

Business on Wall Street in Manhattan

Pgiam/iStock via Getty Images

In the wake of the company’s better-than-expected Q3 2022 financials and guidance raise, Goldman Sachs has opted to upgrade Biogen (NASDAQ:BIIB) to Buy from Neutral, noting an upcoming Phase 3 data readout on its experimental

Recommended For You

Comments (1)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.